LifeStance Health Group, Inc. Q3 FY2025 earnings call

• Achieved 17% organic visit growth due to record organic clinician net adds and productivity improvement. - Reached adjusted EBITDA of $40 million with 11% margins, the highest since IPO. - Implemented initiatives like the Cash Incentive Program, Patient Engagement platform, and tech for phone scheduling, leading to productivity gains. - Partnered with Calm to expand access to mental health care. - Focus on operational and clinical excellence, strategic partnerships, and being employer of choice for clinicians.

Revenue grew 16% year-over-year to $364 million. Visit volumes were 2.3 million, up 17% year-over-year. Adjusted EBITDA was $40 million, with margins of 11%, the highest since the company went public in 2021. Clinician count saw record organic net adds, now roughly 8,000 clinicians. Revenue contribution breakdown: Revenue from visits was driven by 17% organic visit growth, with total revenue per visit flat year-over-year at $158.

• Maintains revenue range $1.41 billion to $1.43 billion. - Raises center margin range by $2 million midpoint to $448 million to $462 million and adjusted EBITDA guidance range by $4 million midpoint to $146 million to $152 million. - Fourth quarter expected revenue $368 million to $388 million, center margin $113 million to $127 million, adjusted EBITDA $37 million to $43 million. - Anticipates mid-teens revenue growth in 2026 driven by low double-digit visit volume increases and low to mid-single-digit rate improvements. - Plans to open 20 to 25 new centers in 2025, lower than previous range.

• Limited exposure to government pay, but general health care landscape uncertainties. - Payer dynamics and legislative shifts could impact. - Competition in the mental health clinician market.

Q: Touch on clinician productivity, context of 17% visits growth vs 11% clinician adds and durability of leverage?

A: Dave Bourdon notes strong productivity improvement, balanced net clinician adds, driven by initiatives like Cash Incentive Program, Patient Engagement platform, and tech/AI, which are durable.

Q: Expand on operating leverage, especially AI side?

A: Dave Bourdon states AI and digital tools are part of driving operating leverage as the business is manual, offering opportunity for technology implementation.

Q: Revenue per visit, what saw in quarter and outlook?

A: Ryan McGroarty says TRPV was flat in quarter, expects full year flat, and 2026 to see low to mid-single-digit rate increases as environment normalizes.

Q: Potential acquisitions, valuations, strategy?

A: Dave Bourdon says good pipeline of acquisition opportunities, valuations appropriate, focus on geographic expansion complementary to organic growth.

Q: Clinician retention impact of productivity initiatives?

A: Dave Bourdon mentions strong net clinician adds due to stable retention, continuing to focus on enhancing clinician experience to move needle on retention.

Q: Specialty Services progression and reception?

A: Dave Bourdon says Specialty Services ~$50M annual revenue, rolling out neuro-psych testing, etc., with great reception, expected to grow faster than core business with higher margins long term.

Q: Revenue guidance, moving pieces, clinic openings?

A: Ryan McGroarty says outperformance in quarter driven by productivity, rebalanced quarters, still see strong Q4 with $14M sequential step-up, clinic openings reduced to 20-25 in 2025 due to timing shifts.

Q: Partnership with Calm, how it works and patient profile?

A: Dave Bourdon says partnership with Calm brings different patient profile, younger demographic, as a new referral partner expanding access.

Q: Thoughts on behavioral health risk to LifeStance and rate commentary for 2026?

A: Dave Bourdon says limited exposure to Medicaid and autism services, unmet need drives utilization, payers focus on access, expect market shift to quality benefiting LifeStance.

Q: Clinicians choosing LifeStance, changes in marketplace?

A: Dave Bourdon says competitive market for mental health clinicians, value proposition resonates, doing well in retention and recruiting within target profile.

Q: 4Q margin down sequentially, investments?

A: Ryan McGroarty says step down in margins due to increasing G&A, pulling forward investments to get strong start in 2026, like accelerating Business Development team.

Q: Business development, patient volumes, Managed Care, referrals, digital selling?

A: Dave Bourdon says strong patient demand, primary referral channel from medical practices, business development team working with them, spend less than 2% of revenue on marketing, bulk of patients from organic/referral partners.

Q: Participation in risk, ACOs, value-based care?

A: Dave Bourdon says no participation in risk today, very limited exposure to government pay (~5% of revenue).

Q: 4Q guidance implications on visit volumes, TRPV, 2026 strategic investments?

A: Ryan McGroarty says no specific guidance on 4Q visit volumes/TRPV, 2026 investments focus on business development, driving efficiency, continuing operating leverage.